Esperion Therapeutics (Pharmaceuticals) Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 240

Employees

  • Stock Symbol
  • ESPR

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $2.19
  • (As of Friday Closing)

Esperion Therapeutics (Pharmaceuticals) General Information

Description

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Contact Information

Formerly Known As
HDL Therapeutics Inc
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Delivery
Stock Exchange
NAS
Corporate Office
  • 3891 Ranchero Drive
  • Suite 150
  • Ann Arbor, MI 48108
  • United States
+1 (734) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Esperion Therapeutics (Pharmaceuticals) Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.19 $2.29 $0.70 - $3.40 $419M 189M 8.53M -$0.97

Esperion Therapeutics (Pharmaceuticals) Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 679,862 489,315 529,935 484,126
Revenue 229,740 116,334 75,475 78,447
EBITDA (27,811) (150,108) (176,349) (222,143)
Net Income (86,507) (209,248) (233,659) (269,108)
Total Assets 373,060 205,796 247,939 381,590
Total Debt 268,988 266,169 260,948 260,196
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Esperion Therapeutics (Pharmaceuticals) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Esperion Therapeutics (Pharmaceuticals)‘s full profile, request access.

Request a free trial

Esperion Therapeutics (Pharmaceuticals) Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Esperion Therapeutics (Pharmaceuticals)‘s full profile, request access.

Request a free trial

Esperion Therapeutics (Pharmaceuticals) Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral
Pharmaceuticals
Ann Arbor, MI
240 As of 2023
00000
00000000 00000

000000

ud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis au
0000 00000000
Miami, FL
00 As of 0000
000000000 -

000000

cididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
000000000000000
Lagos, Nigeria
00 As of 0000
00000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Esperion Therapeutics (Pharmaceuticals) Competitors (60)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Prosolus Corporate Backed or Acquired Miami, FL 00 000000000 -
GlaxoSmithKline Consumer Nigeria Corporation Lagos, Nigeria 00 00000000
Regeneron Pharmaceuticals Formerly VC-backed Tarrytown, NY 00000 00.000 000000000000 00.000
Pfizer Pakistan Corporation Karachi, Pakistan
Helsinn Healthcare Private Equity-Backed Lugano, Switzerland 000 0000000 0000
You’re viewing 5 of 60 competitors. Get the full list »

Esperion Therapeutics (Pharmaceuticals) Patents

Esperion Therapeutics (Pharmaceuticals) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2024521354-A Compositions containing bempedoic acid and tolvabtan and methods of treatment therewith Pending 02-Jun-2021 000000000
EP-4346795-A1 Compositions containing and therapies using bempedoic acid and tolvaptan Pending 02-Jun-2021 000000000
AU-2020295503-A1 Salt forms of bempedoic acid and methods for using the same Inactive 21-Jun-2019 000000000
AU-2020296094-A1 Methods of making bempedoic acid and compositions of the same Pending 21-Jun-2019 000000000
EP-3986860-A1 Salt forms of bempedoic acid and methods for using the same Inactive 21-Jun-2019 A61K31/20
To view Esperion Therapeutics (Pharmaceuticals)’s complete patent history, request access »

Esperion Therapeutics (Pharmaceuticals) Executive Team (21)

Name Title Board Seat Contact Info
Sheldon Koenig Chief Executive Officer & Board Member
Benjamin Halladay Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Betty Jean Chief Strategy Officer
Glenn Brame Chief Technical Operations Officer
Eric Warren Executive
You’re viewing 5 of 21 executive team members. Get the full list »

Esperion Therapeutics (Pharmaceuticals) Board Members (20)

Name Representing Role Since
Alan Fuhrman Self Board Member 000 0000
Antonio Gotto Jr. Self Board Member 000 0000
J. Carroll Esperion Therapeutics (Pharmaceuticals) Chairman & Board Member 000 0000
Jay Shepard Self Board Member 000 0000
Nicole Vitullo Domain Associates Board Member 000 0000
You’re viewing 5 of 20 board members. Get the full list »

Esperion Therapeutics (Pharmaceuticals) Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Esperion Therapeutics (Pharmaceuticals) Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Esperion Therapeutics 28-Apr-2008 0000000000 000 Drug Discovery
Talaria Therapeutics 05-Oct-2000 Merger/Acquisition 00.00 Drug Discovery
To view Esperion Therapeutics (Pharmaceuticals)’s complete acquisitions history, request access »

Esperion Therapeutics (Pharmaceuticals) ESG

Risk Overview

Risk Rating

Updated June, 25, 2023

26.86 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,708

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 884

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 399

Rank

00.00

Percentile

To view Esperion Therapeutics (Pharmaceuticals)’s complete esg history, request access »

Esperion Therapeutics (Pharmaceuticals) FAQs

  • When was Esperion Therapeutics (Pharmaceuticals) founded?

    Esperion Therapeutics (Pharmaceuticals) was founded in 1998.

  • Who is the founder of Esperion Therapeutics (Pharmaceuticals)?

    Anders Wiklund is the founder of Esperion Therapeutics (Pharmaceuticals).

  • Who is the CEO of Esperion Therapeutics (Pharmaceuticals)?

    Sheldon Koenig is the CEO of Esperion Therapeutics (Pharmaceuticals).

  • Where is Esperion Therapeutics (Pharmaceuticals) headquartered?

    Esperion Therapeutics (Pharmaceuticals) is headquartered in Ann Arbor, MI.

  • What is the size of Esperion Therapeutics (Pharmaceuticals)?

    Esperion Therapeutics (Pharmaceuticals) has 240 total employees.

  • What industry is Esperion Therapeutics (Pharmaceuticals) in?

    Esperion Therapeutics (Pharmaceuticals)’s primary industry is Pharmaceuticals.

  • Is Esperion Therapeutics (Pharmaceuticals) a private or public company?

    Esperion Therapeutics (Pharmaceuticals) is a Public company.

  • What is Esperion Therapeutics (Pharmaceuticals)’s stock symbol?

    The ticker symbol for Esperion Therapeutics (Pharmaceuticals) is ESPR.

  • What is the current stock price of Esperion Therapeutics (Pharmaceuticals)?

    As of 21-Jun-2024 the stock price of Esperion Therapeutics (Pharmaceuticals) is $2.19.

  • What is the current market cap of Esperion Therapeutics (Pharmaceuticals)?

    The current market capitalization of Esperion Therapeutics (Pharmaceuticals) is $419M.

  • What is Esperion Therapeutics (Pharmaceuticals)’s current revenue?

    The trailing twelve month revenue for Esperion Therapeutics (Pharmaceuticals) is $230M.

  • Who are Esperion Therapeutics (Pharmaceuticals)’s competitors?

    Prosolus, GlaxoSmithKline Consumer Nigeria, Regeneron Pharmaceuticals, Pfizer Pakistan, and Helsinn Healthcare are some of the 60 competitors of Esperion Therapeutics (Pharmaceuticals).

  • What is Esperion Therapeutics (Pharmaceuticals)’s annual earnings per share (EPS)?

    Esperion Therapeutics (Pharmaceuticals)’s EPS for 12 months was -$0.97.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »